Loading
A phase 1/2 trial in lung cancer, run by University Hospital, Lille, now recruiting.
EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. is a phase 1/2, interventional study registered as NCT06448572 by University Hospital, Lille, with a registry enrolment figure of 21 participants, started 2024-07-16 and due to reach its primary completion in 2028-10-01. Interventions recorded: EXL01. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression-free survival rate (PFS Rate) for the assessment of efficacy, defined as the rate of alive and non-progressive subjects as per iRECIST 1.1 over the study subjects.. Lung eligibility wording from the registry: "Histologically or cytologically documented inoperable advanced/metastatic NSCLC". Sites: France. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.